Markets
INO

Why Inovio Pharmaceuticals Stock Is Down Today

What happened?

Shares of Inovio Pharmaceuticals (NASDAQ: INO) are down by 6.2% as of 10:43 a.m. EDT, despite the company not reporting any news. We can probably attribute these losses to a Tweet from Citron Research, which is run by short-seller Andrew Left. 

So what

In the Tweet, Citron Research claims Inovio's stock will fall back to $5, which would be a significant drop from its current levels. The biotech's shares are worth $16.09 apiece as of this writing. Why think Inovio's stock will fall off a cliff? Citron Research mentions that other companies looking to develop vaccines for COVID-19 are currently running late-stage clinical trials that feature thousands of participants. For instance, Moderna started a phase 3 study in July, and the company said it would enroll up to 30,000 participants.

five downward pointing arrows on a blackboard.

Image source: Getty Images.

Meanwhile, AstraZeneca and the partnership of Pfizer and BioNTech will enroll up to 30,000 and 44,000 participants to their ongoing clinical trials, respectively. By contrast, Inovio's COVID-19 candidate, INO-4800, was tested in a phase 1/2 clinical trial with only 40 volunteers.

Now what

Inovio said it would kick off a phase 2/3 study this month, but the company has yet to do so. The biotech does plan to produce at least 100 million doses of its candidate next year. However, as Citron Research points out, other companies seem far ahead of Inovio in this race. Pfizer's CEO, Albert Bourla, claimed the company will know whether its vaccine works by the end of October. If it does, it could obtain regulatory approval or emergency use authorization within the next few months.

The other players in this race also seem more likely to launch their products on the market before Inovio. While some unforeseen event could prevent them from doing so, thereby allowing Inovio to grab the lead (clinical trials are, after all, rife with potential pitfalls), there's no reason to suppose something like that will happen. That being said, the market opportunity is vast, which means Inovio could still profit in the long run. But as things stand, investors looking for exposure to the coronavirus vaccine race would be better off staying away from Inovio and choosing one of the other top contenders. 

10 stocks we like better than Inovio Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Inovio Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of August 1, 2020

 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

INO AZN PFE MRNA BNTX

Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More